Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | US

Overview

Corporate Details

ISIN(s):: US4718712023 (+3 more)
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
FRACTYL HEALTH, INC. Developing gut-targeted endoscopic and gene therapies for obesity and type 2 diabetes.	United States of America	GUTS
Friulchem CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.	Italy	FCM
Fuji Pharma Co.,Ltd. Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.	Japan	4554
Fulcrum Therapeutics, Inc. Develops gene-modulating small molecule drugs for rare, genetically defined diseases.	United States of America	FULC
Fuso Pharmaceutical Industries,Ltd. Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.	Japan	4538
FutureChem Co., Ltd. Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.	South Korea	220100
Future Medicine Co., Ltd. Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.	South Korea	341170
G2GBIO, Inc. Develops long-acting injectable therapies for chronic diseases and cancer.	South Korea	456160
Gabather AB Developing novel GABAA receptor drugs for neuropsychiatric disorders.	Sweden	GABA
Galapagos NV Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.	Belgium	GLPG